

Study 06-008
Assessed for Eligibility: *n* = 1853

	SXB	PBO	Total
Randomized	365	183	548
Discontinued	142 39%	72 39%	214 39%
Adverse Events	21%	11%	18%
Lack of Efficacy	7%	16%	10%
Withdrew Consent	7%	6%	7%
Other	4%	6%	5%

Completed	223 61%	111 61%	334 61%
-----------	------------	------------	------------

Enrolled in 06-010*	183 82%	86 77%	269 81%
---------------------	------------	-----------	------------

Study 06-009
Assessed for Eligibility: *n* = 1544

	SXB	PBO	Total
Randomized	385	188	573
Discontinued	140 36%	57 30%	197 34%
Adverse Events	18%	6%	14%
Lack of Efficacy	10%	12%	10%
Withdrew Consent	3%	3%	3%
Other	5%	9%	6%

Completed	245 64%	131 70%	376 66%
-----------	------------	------------	------------

Enrolled in 06-010*	191 78%	101 77%	292 78%
---------------------	------------	------------	------------

Study 06-010
Assessed for Eligibility*: *n* = 561 (79%)

	Prior Study Treatment		
	SXB	PBO	Total*
Treated	374	186	560 (79%)

	Prior Study Treatment		
	SXB	PBO	Total
Discontinued	150 40%	91 49%	241 43%
Adverse Events	21%	27%	23%
Lack of Efficacy	6%	9%	7%
Withdrew Consent	7%	6%	6%
Lost to Follow-up	3%	2%	3%
Investigator Decision	2%	1%	1%
Protocol Deviation/Violation	1%	1%	1%
Other	1%	1%	1%
Sponsor Decision	0%	2%	1%

	Prior Study Treatment		
	SXB	PBO	Total
Completed	224 60%	95 51%	319 57%